Evidence map›Paper›PMID 39738821›Full record

ArticleInflammation2025

F2RL1 Inhibition Alleviates Lipotoxicity-Induced Kidney Injury Through the Hippo Pathway in Diabetic Kidney Disease.

Hui Wang, Wei Wang, Yao Jiang, Siyuan Cui, Yulin Kong, Yong Q Chen, Shenglong Zhu

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Hui Wang *Wuxi School of Medicine, Jiangnan University, Wuxi, China.
Wei Wang *The Second Clinical Medical School, Xuzhou Medical University, Xuzhou, Jiangsu, China.
Yao JiangWuxi School of Medicine, Jiangnan University, Wuxi, China.
Siyuan CuiThe Affiliated Wuxi No.2, People's Hospital of Nanjing Medical University , Wuxi, China.
Yulin KongWuxi School of Medicine, Jiangnan University, Wuxi, China.
Yong Q ChenWuxi School of Medicine, Jiangnan University, Wuxi, China. yqchen@jiangnan.edu.cn.
Shenglong ZhuWuxi School of Medicine, Jiangnan University, Wuxi, China. shenglongzhu@jiangnan.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diabetic kidney disease (DKD), which is emerging as a pervasive global health concern and a considerable economic burden, is characterized by a detrimental effect on renal function and structure. Recent research indicates that the progression of DKD is facilitated by lipotoxic injury to tubular epithelial cells (TECs). However, the specific mechanisms that contribute to this cellular damage have yet to be fully elucidated. Our results revealed a significant upregulation of F2RL1 in vivo and in vitro models, which was positively correlated with the expression of inflammatory factors. Knockdown of F2RL1 significantly reduced inflammatory response in palmitate-stimulated HK-2 cells. Mechanistically, F2RL1 might exacerbate lipotoxicity-induced DKD through the modulation of the Hippo signaling pathway. Collectively, these findings suggest that modulating F2RL1 expression may be a strategic approach to mitigate the inflammatory damage to RTECs associated with DKD, potentially through its involvement in the Hippo signaling pathway. Given these findings, F2RL1 merits consideration as a candidate therapeutic target for DKD.

Indexed as

Diabetic NephropathiesProtein Serine-Threonine KinasesAnimalsCell LineHippo Signaling PathwayHumansMiceSignal TransductionProtein Serine-Threonine KinasesDiabetic kidney diseaseF2RL1Hippo pathwayLipotoxicityRNA sequencing

Identifiers

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.